Publicaciones en las que colabora con Encarnación González Rodriguez (7)

2022

  1. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

    Clinical and Translational Oncology, Vol. 23, Núm. 8, pp. 1520-1528

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

2015

  1. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: The phase II AVAXIRI study

    BMC Cancer, Vol. 15, Núm. 1

2013

  1. Bevacizumab plus chemotherapy continued beyond first progression in patients withmetastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

    Annals of Oncology, Vol. 24, Núm. 9, pp. 2342-2349

2010

  1. SEOM clinical guidelines for the treatment of advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 729-734

2009

  1. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: A phase II study of the Spanish GOTI group

    British Journal of Cancer, Vol. 101, Núm. 7, pp. 1039-1043